Sanara Competitors

Stocks . USA . 
Stock . Sanara Medtech
SMTI Stock  USD 22.25  0.54  2.37%   
Sanara Medtech competes with Stereotaxis, Exagen, NeoGenomics, LifeMD, and High Tide; as well as few others. The company conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. Analyzing Sanara Medtech competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Sanara Medtech to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Sanara Medtech Correlation with its peers.
For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.

Sanara Medtech vs Viemed Healthcare Correlation

Good diversification

The correlation between Sanara Medtech and VMD is -0.05 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Sanara Medtech and VMD in the same portfolio, assuming nothing else is changed.

Moving against Sanara Stock

  0.5PFE Pfizer Inc Aggressive PushPairCorr
  0.47TLKMF Telkom Indonesia TbkPairCorr
  0.45CSCO Cisco SystemsPairCorr
  0.4MRK Merck CompanyPairCorr
  0.36TLK Telkom Indonesia TbkPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Sanara Medtech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
17.6522.2526.85
Details
Intrinsic
Valuation
LowRealHigh
19.0623.6628.26
Details

Sanara Medtech Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Sanara Medtech and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Sanara and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Sanara Medtech does not affect the price movement of the other competitor.

High positive correlations

LFMD
+ 0.89
XGN
TBRG
+ 0.88
SGHT
VMD
+ 0.81
NEO
HITI
+ 0.81
LFMD
HITI
+ 0.79
XGN
TRDA
+ 0.75
TBRG
  

High negative correlations

NEO
- 0.89
XGN
SGHT
- 0.83
LFMD
TBRG
- 0.82
LFMD
LFMD
- 0.76
NEO
SGHT
- 0.76
STXS
VMD
- 0.73
XGN

Risk-Adjusted Indicators

There is a big difference between Sanara Stock performing well and Sanara Medtech Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Sanara Medtech's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
STXS  2.69 (0.28) 0.00 (0.10) 0.00 
 0.00 
 4.69 
(4.88)
 18.81 
XGN  2.48 (1.56) 0.00 (0.92) 0.00 
 0.00 
 2.88 
(6.15)
 17.46 
NEO  1.98  0.28  0.10  0.52  2.21 
(2.16)
 4.99 
(4.03)
 13.39 
LFMD  3.63 (1.07) 0.00 (0.26) 0.00 
 0.00 
 8.13 
(7.02)
 28.11 
HITI  2.15 (0.43) 0.00 (0.53) 0.00 
 0.00 
 4.78 
(4.20)
 17.53 
SGHT  3.32  0.17  0.09  0.16  3.43 
(4.04)
 9.34 
(5.67)
 25.08 
TBRG  1.60  0.05  0.00  0.23  1.99 
(1.78)
 3.41 
(3.04)
 9.75 
OMI  4.15 (1.38) 0.00  4.63  0.00 
 0.00 
 9.77 
(14.66)
 27.99 
TRDA  2.88  1.02  0.38  1.24  2.04 
(3.54)
 6.98 
(4.00)
 15.00 
VMD  1.45  0.06  0.02  0.18  1.68 
(1.61)
 3.15 
(2.79)
 8.29 

Sanara Medtech Competitive Analysis

The better you understand Sanara Medtech competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Sanara Medtech's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Sanara Medtech's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SMTI STXS XGN NEO LFMD HITI SGHT TBRG OMI TRDA
 2.37 
 22.25 
Sanara
 0.73 
 2.73 
Stereotaxis
 3.38 
 4.89 
Exagen
 2.21 
 12.97 
NeoGenomics
 2.26 
 3.62 
LifeMD
 0.77 
 2.61 
High
 0.63 
 6.42 
Sight
 2.93 
 20.75 
TruBridge
 12.38 
 2.36 
Owens
 3.63 
 11.71 
Entrada
Market Volatility
(90 Days Market Risk)
Not too volatile
Risky
Moderately volatile
Not too volatile
Very risky
Unstable
Moderately volatile
Not too volatile
Dangerous
Somewhat reliable
Market Performance
(90 Days Performance)
Weakest
Weakest
Weakest
Fair
Weakest
Weakest
Fair
Soft
Weakest
Solid
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
Low
Risky
Small
Average
Small
Average
Average
Hazard
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Strong Buy
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Cautious Hold
Strong Sell
Hold
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Not Rated
Strong Buy
Current Ratio
2.86
2.96
9.3
7.53
0.52
1.23
16.73
0.19
1.55
14.05
Net Asset
88.09 M
46.72 M
44.69 M
1.64 B
72.46 M
246.21 M
142.84 M
394.43 M
4.66 B
526.32 M
Profit Margin
-0.37
-0.79
-0.3
-0.16
-0.0321
-0.0172
-0.61
0.0103
-0.12
-1.68
EBITDA
(1.86 M)
(23.77 M)
(11.14 M)
(1.51 M)
(6.65 M)
33.78 M
(45.9 M)
34.94 M
515.18 M
50.78 M
Operating Margin
0.11
-0.7
-0.18
-0.0809
-0.0327
0.036
-0.26
0.0901
0.0808
-29.15
Current Valuation
234.58 M
256.99 M
96.66 M
1.88 B
154.1 M
234.77 M
278.23 M
448.92 M
2.38 B
157.44 M
Price To Book
32.87
40.96
5.86
1.95
130.39
2.18
5.13
1.67
1.07
1.27
Retained Earnings
(37.78 M)
(561.73 M)
(294.33 M)
(325.78 M)
(236.25 M)
(205.93 M)
(346.3 M)
(14.95 M)
6.02 M
(129.34 M)
Current Asset
N/A
17.14 M
N/A
82.36 M
N/A
N/A
N/A
N/A
1.97 B
N/A
Five Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
3.74
N/A
Beta
1.06
1.44
1.87
1.57
1.45
0.96
2.41
0.61
1.36
-0.12
Number Of Employees
141
139
209
2.2 K
304
1.75 K
216
3.2 K
23.2 K
183
Shares Outstanding
8.94 M
93.32 M
22.66 M
129.39 M
48.14 M
87.11 M
52.87 M
15.01 M
77.35 M
38.22 M
Cash Flow From Operations
(23.78 K)
(8.5 M)
(13.28 M)
7.02 M
17.51 M
35.55 M
(22.35 M)
32.13 M
161.5 M
(41.56 M)
Total Debt
32.29 M
6.01 M
23 M
605.33 M
25.1 M
74.61 M
40.36 M
174.81 M
2.14 B
59.21 M
Return On Equity
-0.28
-1.7
-1.23
-0.13
-22.43
-0.0652
-0.58
0.0204
-1.96
-0.27
Return On Asset
0.0113
-0.26
-0.15
-0.0303
-0.0285
0.0328
-0.2
0.0514
0.0375
-0.16
Number Of Shares Shorted
197.94 K
2.92 M
1.08 M
7.87 M
5.1 M
396.36 K
983.26 K
564.42 K
10.05 M
760.34 K
Book Value Per Share
0.69
0.069
0.81
6.5
0.028
1.25
1.23
12.42
-5.56
9.5
Current Liabilities
N/A
16.14 M
N/A
40.06 M
N/A
N/A
N/A
N/A
1.06 B
N/A
Total Asset
88.09 M
46.72 M
44.69 M
1.64 B
72.46 M
246.21 M
142.84 M
394.43 M
4.66 B
526.32 M
Debt To Equity
0.008
0.18
0.55
0.59
0.46
0.31
0.18
6.3
2.99
0.12
Short Ratio
4.5
7.05
3.61
4.93
4.07
6.16
3.54
6.0
5.38
4.2
Target Price
40.0
4.2
14.71
14.43
9.25
6.0
9.35
22.67
5.44
16.5
Shares Owned By Institutions
13.09
46.57
55.98
98.74
42.56
13.6
49.6
69.0
97.45
78.37
Market Capitalization
203.64 M
256.64 M
107.42 M
1.64 B
171.36 M
222.13 M
329.92 M
302.63 M
216.57 M
431.88 M
Price To Earning
N/A
21.61
N/A
272.37
N/A
N/A
N/A
N/A
42.0
N/A
Price To Earnings To Growth
N/A
N/A
N/A
3.02
N/A
N/A
N/A
0.88
4.07
N/A
Price To Sales
2.0
8.53
1.69
2.32
0.69
0.39
4.34
0.87
0.0201
7.02
Net Income
(9.91 M)
(24.05 M)
(15.12 M)
(78.73 M)
(18.73 M)
(3.81 M)
(51.51 M)
(20.44 M)
(362.69 M)
65.63 M
Earnings Per Share
-0.72
-0.28
-0.93
-0.89
-0.25
-0.08
-0.9
0.24
-5.69
-2.57
Shares Owned By Insiders
65.31
29.52
14.61
1.26
15.03
12.02
20.69
18.08
3.37
12.23
Revenue
86.67 M
26.92 M
55.64 M
660.57 M
212.45 M
522.31 M
79.87 M
342.65 M
10.7 B
210.78 M
Working Capital
18.02 M
4.84 M
22.95 M
294.78 M
(11.52 M)
24.31 M
124.31 M
37.3 M
147.28 M
400.56 M
Cash And Equivalents
12.68 M
30.94 M
76.39 M
465.95 M
5.84 M
18.74 M
220.1 M
159.38 K
49.38 M
244.25 M
Cash Per Share
1.53
0.41
4.7
3.7
0.19
0.27
4.6
0.02
0.74
7.81
Gross Profit
93.98 M
15.96 M
38.07 M
307.81 M
217.18 M
146.76 M
65.44 M
183.38 M
2.24 B
(80.2 M)
Day Typical Price
22.48
2.76
4.89
12.94
3.64
2.64
6.4
20.63
2.29
11.68
Accumulation Distribution
1539.66
17146.85
51771.38
75262.49
33659.83
15904.78
34933.54
1579.89
0.13
16657.42
Market Facilitation Index
0.0
N/A
N/A
N/A
N/A
N/A
0.0
0.0
0.32
0.0
Daily Balance Of Power
(0.73)
(0.22)
0.4848
0.4
0.6154
0.1538
0.0606
0.8806
0.8125
0.3942
Period Momentum Indicator
(0.54)
(0.02)
0.16
0.28
0.08
0.02
0.04
0.59
0.26
0.41
Rate Of Daily Change
0.98
0.99
1.03
1.02
1.02
1.01
1.01
1.03
1.12
1.04
Day Median Price
22.6
2.78
4.89
12.93
3.66
2.66
6.39
20.57
2.26
11.66
Price Action Indicator
(0.62)
(0.06)
0.085
0.18
0.005
(0.04)
0.05
0.48
0.23
0.26
Relative Strength Index
40.71
53.24
23.3
58.47
41.63
42.58
43.7
46.59
38.91
64.21
Coefficient Of Variation
(1,061)
(2,762)
(232.65)
759.22
(657.63)
(832.68)
1091.98
2117.02
(428.06)
320.85
Mean Deviation
2.83
2.69
2.48
1.98
3.63
2.15
3.32
1.6
4.15
2.88
Jensen Alpha
(0.52)
(0.28)
(1.56)
0.2841
(1.07)
(0.43)
0.1739
0.0526
(1.38)
1.02
Total Risk Alpha
(1.03)
(0.61)
(1.83)
0.0019
(1.44)
(0.74)
(0.17)
(0.18)
(2.17)
0.6486
Sortino Ratio
N/A
N/A
N/A
0.097
N/A
N/A
0.0867
(0)
N/A
0.3799
Downside Variance
N/A
N/A
N/A
6.76
N/A
N/A
13.49
4.98
N/A
7.06
Standard Deviation
4.6
3.7
3.26
2.7
5.11
2.93
4.61
2.11
6.0
3.57
Kurtosis
12.57
3.26
2.04
0.7809
1.74
2.98
2.0
0.3529
2.18
(0.22)
Potential Upside
5.6
4.69
2.88
4.99
8.13
4.78
9.34
3.41
9.77
6.98
Treynor Ratio
(0.53)
(0.10)
(0.92)
0.5241
(0.26)
(0.53)
0.1625
0.2276
4.63
1.24
Maximum Drawdown
26.42
18.81
17.46
13.39
28.11
17.53
25.08
9.75
27.99
15.0
Variance
21.13
13.68
10.63
7.31
26.07
8.59
21.28
4.45
35.98
12.76
Market Risk Adjusted Performance
(0.52)
(0.09)
(0.91)
0.5341
(0.25)
(0.52)
0.1725
0.2376
4.64
1.25
Risk Adjusted Performance
(0.06)
(0.02)
(0.31)
0.1045
(0.10)
(0.08)
0.076
0.0414
(0.16)
0.2381
Skewness
(2.19)
(0.85)
(1.04)
0.3119
0.4674
1.01
1.03
(0.37)
(0.76)
0.4593
Semi Deviation
N/A
N/A
N/A
2.21
N/A
N/A
3.43
1.99
N/A
2.04
Information Ratio
(0.12)
(0.06)
(0.46)
0.0932
(0.17)
(0.16)
0.069
(0)
(0.25)
0.2826
Value At Risk
(4.68)
(4.88)
(6.15)
(4.03)
(7.02)
(4.20)
(5.67)
(3.04)
(14.66)
(4.00)
Expected Short fall
N/A
N/A
N/A
(2.16)
N/A
N/A
(4.04)
(1.78)
N/A
(3.54)
Downside Deviation
N/A
N/A
N/A
2.6
N/A
N/A
3.67
2.23
N/A
2.66
Semi Variance
N/A
N/A
N/A
4.87
N/A
N/A
11.79
3.97
N/A
4.15

Sanara Medtech Competition Performance Charts

Five steps to successful analysis of Sanara Medtech Competition

Sanara Medtech's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Sanara Medtech in relation to its competition. Sanara Medtech's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Sanara Medtech in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Sanara Medtech's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Sanara Medtech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Sanara Medtech position

In addition to having Sanara Medtech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Warren Buffett Holdings Thematic Idea Now

Warren Buffett Holdings
Warren Buffett Holdings Theme
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Sanara Medtech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanara Medtech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanara Medtech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanara Medtech Stock:
How To Invest In Sanara
Details
Is Sanara Stock a good investment?
Details
What is Sanara Medtech's Net Worth?
Details
Top Sectors
View
Check out Sanara Medtech Correlation with its peers.
For more detail on how to invest in Sanara Stock please use our How to Invest in Sanara Medtech guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanara Medtech. If investors know Sanara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanara Medtech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sanara Medtech is measured differently than its book value, which is the value of Sanara that is recorded on the company's balance sheet. Investors also form their own opinion of Sanara Medtech's value that differs from its market value or its book value, called intrinsic value, which is Sanara Medtech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanara Medtech's market value can be influenced by many factors that don't directly affect Sanara Medtech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Sanara Medtech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanara Medtech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanara Medtech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY